Logo

Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease

Share this
Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease

Equillium Reports Initiation of P-III (EQUATOR) Study for Itolizumab as 1L Treatment of Acute Graft-Versus-Host Disease

Shots:

  • The P-III (EQUATOR) study evaluates the efficacy and safety of itolizumab vs PBO in a ratio (1:1) in 200 adult and adolescent patients with Grade II or III-IV aGVHD with lower GI involvement in combination with high doses of corticosteroids at North America, Europe, Asia, and Australia. The study is based on the (EQUATE) study
  • The primary objective of the study is CR rate @ Day 29 & will evaluate to achieve early disease response while the 2EPs objective is ORR @ Day 29 and durability of CR rate from Day 29 through Day 99 & will evaluate DoR, corticosteroid use, survival outcomes & chronic GVHD incidence
  • Itolizumab is an anti-CD6 mAb that selectively targets the CD6-ALCAM pathway. The therapy has received FTD & ODD from the US FDA for the treatment of patients with aGVHD

Ref: Equillium | Image: Equillium

Click here to­ read the full press release 

Neha

Neha Madan is a content writer at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions